RecruitingPhase 1Phase 2NCT05745623

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Enrollment

70 participants

Start Date

Dec 27, 2022

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors Harboring NTRK Fusion Primary Central Nervous System Tumors Harboring NTRK Fusion

Summary

A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ICP-723 for people with advanced solid tumors harboring ntrk fusion and primary central nervous system tumors harboring ntrk fusion. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGICP-723

ICP-723 tablet administered orally，once a day，for every 28 days as one cycle

Locations(1)

Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05745623